Or Refractory Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2023-12-26
Clinical Trial Update: Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers [Phase 1]
Phase 1 trial evaluating KITE-439 in HLA-A*02:01+ adults with HPV16+ relapsed/refractory cancers was terminated; results posted in 2023.